anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a medicine effective as a therapeutic agent for glomerular diseases represented by glomerular nephritis, nephrotic syndrome, drug renal disorder, etc. CONSTITUTION:A medicine comprises (-)-epicatechin-3-O-gallate of the formula as active ingredient. The compound is obtained from rhizome of Pheum palmatum of crude drug by operation such as extraction, purification, etc. The compound is orally or parenterally administered. In order to exhibit given effects as an oral medicine, 100mg-6g of the compound is administered dividedly several times a day. In order to show given effects as a parenteral medicine, 1-100mg of the compound is applied daily by intravenous drip infusion, hypodermic injection and intramuscular injection.
PURIXAN can cause fetal harm when administered to a pregnant woman. An increased incidence of miscarriage has been reported in women who received mercaptopurine in the first trimester of pregnancy. Adverse embryo-fetal findings, including miscarriage and stillbirth, have been reported in women who received mercaptopurine after the first trimester of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with PURIXAN and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with PURIXAN and for 3 months after the last dose [see Use in Specific Populations (8.1,8.3)].
Primary dysmenorrhea (PD), a prevalent menstrual condition characterized by pelvic pain during the menstrual cycle, significantly impacts the quality of life of women and produces increased pain sensitivity that can persist throughout the menstrual cycle. However, scientific literature has not studied whether there are implications for alterations in muscle function and endurance in the abdominopelvic region during the non-painful phases of the menstrual cycle. The aim of this study was to compare muscle function and endurance capacity in the abdominopelvic region in women with PD versus women without this condition. An observational, cross-sectional study was designed to analyze muscle activation and endurance capacity using electromyography (EMG) during McGill exercises. Forty-four women were included, 22 with PD and 22 without dysmenorrhea. The results did not indicate significant differences in muscle activation and endurance of the abdominopelvic musculature between the two groups (p > 0.05). However, the analysis suggests that women with primary dysmenorrhea might develop compensatory strategies that allow them to maintain physical function despite their condition. These results suggest that the approach to PD could focus more on pain management rather than physical functionality, and more studies are needed from a comprehensive approach to more accurately evaluate the relationship between PD and muscle function.
This invention relates to a nonspecific anti-viral and anti-bacterial solution for prevention and treatment of conjunctivitis. In these days of frequent infections due to bacteria and virus lot of problems owing to such infections especially on different organs are faced. People are experiencing such a highly infectious disease of eye commonly known as conjunctivitis that affects people of any locality rapidly in the form of epidemic. In fact there is no effective medicine for Conjunctivitis. Generaly in case of little infection it helps to bathe the eyes with water or water with a pinch of salt in it. Conjunctivitis is often very contagious. It is nesessary to wash hands after touching infected eyes as it is very easy to infect others by spreading the germs on the fingers or on tissues etc. In the case of a bacterial infection, antibiotic eye drops or ointments are needed. In some rare infections, antibiotics are also given by mouth. If the problem is due to a virus infection, then it will not respond to antibiotics, and the body will have to fight off the infection. Doctors may prescribe drops or ointment, or both. Drops stay in the eyes for a shorter period, but ointment tends to blur the vision. Sometimes the doctor may prescribe drops by day, with ointment at night. But the treatment is not comfortable and not so effective. Moreover, it is ineffective against virus infection. To solve these disgusting problems as regards prevention and curing of such a painful disease an effective and purposeful medicine named “conheal” has been invented, which has proved and established its excellence as medicine & preventive for Conjunctivitis . The reguler use of conheal as eye-drop prevents eyes from any kind of bacterial and viral infection. Conheal is the distill water based solution of [K2SO4, Al2(SO4)3, 24H2O], usually known as common Alum, of normality 0.0084(N). It is nonspecific anti-viral, antibactirial liquid to cure a serious disease causing out of viral/bacterial infection of eye known as conjunctivitis.
In short-term controlled trials in alcohol-dependent patients, more patients treated with Naltrexone Injection 380 mg (11%) and oral naltrexone (17%) shifted from normal creatinine phosphokinase (CPK) levels before treatment to abnormal CPK levels at the end of the trials, compared to placebo patients (8%). In open-label trials, 16% of patients dosed for more than 6 months had increases in CPK. For both the oral naltrexone and Naltrexone Injection 380 mg groups, CPK abnormalities were most frequently in the range of 1–2 x ULN. However, there were reports of CPK abnormalities as high as 4x ULN for the oral naltrexone group, and 35 x ULN for the Naltrexone Injection 380 mg group. Overall, there were no differences between the placebo and naltrexone (oral or injectable) groups with respect to the proportions of patients with a CPK value at least three times the upper limit of normal. No factors other than naltrexone exposure were associated with the CPK elevations.

More opioid-dependent patients treated with Naltrexone Injection 380 mg (39%) shifted from normal creatinine phosphokinase (CPK) levels before treatment to abnormal CPK levels during the study as compared to patients treated with placebo (32%). There were reports of CPK abnormalities as high as 41.8 x ULN for the placebo group, and 22.1 x ULN for the Naltrexone Injection 380 mg group.
OBJECTIVES: The utility of intraoperative electrocorticography (ECoG)-guided resective surgery for pediatric long-term epilepsy-associated tumors (LEATs) with antiseizure medication (ASM) resistant epilepsy is not supported by robust evidence. As epilepsy networks and their ramifications are different in children from those in adults, the impact of intraoperative ECoG-based tailored resections in predicting prognosis and influencing outcomes may also differ. We evaluated this hypothesis by comparing the outcomes of resections with and without the use of ECoG in children and adults by a randomized study.
METHODS: From June 2020 to January 2022, 42 patients (17 children and 25 adults) with LEATs and antiseizure medication (ASM)-resistant epilepsy were randomly assigned to one of the 2 groups (ECoG or no ECoG), prior to surgical resection. The 'no ECoG' arm underwent gross total lesion resection (GTR) without ECoG guidance and the ECoG arm underwent GTR with ECoG guidance and further additional tailored resections, as necessary. Factors evaluated were tumor location, size, lateralization, seizure duration, preoperative antiepileptic drug therapy, pre- and postresection ECoG patterns and tumor histology. Postoperative Engel score and adverse event rates were compared in the pediatric and adult groups of both arms. Eloquent cortex lesions and re-explorations were excluded to avoid confounders.
RESULTS: Forty-two patients were included in the study of which 17 patients were in the pediatric cohort (age < 18 years) and 25 in the adult cohort. The mean age in the pediatric group was 11.11 years (SD 4.72) and in the adult group was 29.56 years (SD 9.29). The mean duration of epilepsy was 9.7 years (SD 4.8) in the pediatric group and 10.96 (SD 8.8) in the adult group. The ECoG arm of LEAT resections had 23 patients (9 children and 14 adults) and the non-ECoG arm had 19 patients (8 children and 11 adults). Three children and 3 adults from the ECoG group further underwent ECoG-guided tailored resections (average 1.33 additional tailored resections/per patient.).The histology of the tailored resection specimen was unremarkable in 3/6 (50%).Overall, the commonest histology in both groups was ganglioglioma and the temporal lobe, the commonest site of the lesion. 88.23% of pediatric cases (n = 15/17) had an excellent outcome (Engel Ia) following resection, compared to 84% of adult cases (n = 21/25) at a mean duration of follow-up of 25.76 months in children and 26.72 months in adults (p = 0.405).There was no significant difference in seizure outcomes between the ECoG and no ECoG groups both in children and adults, respectively (p > 0.05). Additional tailored resection did not offer any seizure outcome benefit when compared to the non-tailored resections.
CONCLUSIONS: The use of intraoperative electrocorticography in LEATs did not contribute to postoperative seizure outcome benefit in children and adults. No additional advantage or utility was offered by ECoG in children when compared to its use in adults. ECoG-guided additional tailored resections did not offer any additional seizure outcome benefit both in children and adults.
Patients randomly allocated to this arm will receive treatment immediately. They will receive 6-12 sessions of ACT while patients allocated to the waitlist control arm do no receive any treatment.
A method and system for evaluating a subject's weight calculates a moving average of the weight of the subject based on several consecutive weight measurements e.g. on consecutive days. Rather than looking for absolute weight gains of e.g. 2 kg in 48 hours, as with currently accepted guidelines, each new measurement is compared with the calculated moving average, and a first form of alert is generated if the new measurement differs from the calculated moving average by more than a with expected range threshold amount such as by one standard deviation. If the first form of alert is generated consecutively on a predetermined number of successive iterations, a second form of alert is generated different from the first form of alert. The system and method does not assume a stable underlying patient weight, and absolute weight gains over e.g. a 48 hour period are not used as in currently accepted guidelines, which results in earlier alerting of clinical deteriorations and greatly increased sensitivity relative to published guideline methods.
Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra − , and integrin α4β7 − , express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In one embodiment of the invention, the active agent is a CCR4 agonist, that acts to enhance T cell localization. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.
INTRODUCTION: Maternal disorders are the third leading cause of sepsis globally, accounting for 5.7 million (12%) cases in 2017. There are increasing concerns about the emergence of antimicrobial resistance (AMR) in bacteria commonly causing maternal sepsis. Our aim is to describe the protocol for a clinical and microbiology laboratory study to understand risk factors for and the bacterial etiology of maternal sepsis in a tertiary Obstetrics and Gynaecology Hospital.
METHODS: This case-control study aims to recruit 100 cases and 200 controls at Tu Du Hospital in Ho Chi Minh City, Vietnam, which had approximately 55,000 births in 2022. Women aged ≥ 18 years and ≥ 28 weeks gestation having a singleton birth will be eligible for inclusion as cases or controls, unless they have an uncomplicated localised or chronic infection, or an infection with SARS-CoV-2. Cases will include pregnant or recently pregnant women with sepsis recognised between the onset of labour and/or time of delivery/cessation of pregnancy for up to 42 days post-partum. Sepsis will be defined as suspected or confirmed infection with an obstetrically modified Sequential Organ Failure Assessment score of ≥ 2, treatment with intravenous antimicrobials and requested cultures of any bodily fluid. Controls will be matched by age, location, parity, mode of delivery and gestational age. Primary and secondary outcomes are risk factors associated with the development of maternal sepsis, the frequency of adverse outcomes due to maternal sepsis, bacterial etiology and AMR profiles of cases and controls.
DISCUSSION: This study will improve understanding of the epidemiology and clinical implications of maternal sepsis management including the presence of AMR in women giving birth in Vietnam. It will help us to determine whether women in this setting are receiving optimal care and to identify opportunities for improvement.
<P>PROBLEM TO BE SOLVED: To provide a lipase inhibitor safe and high in effect, daily ingestible continuously, and to provide a method for producing the same and to provide a composition for anti-obesity.  <P>SOLUTION: The lipase inhibitor principally comprises a lower alcohol extract of pretreated kale obtained by removing water-soluble component or drying the same. The method for producing the lipase inhibitor comprises a pretreating process soaking kale or its dried product in water to distribute it into a water-soluble component and a residue, and a process extracting the effective component with a lower alcohol by soaking the residue in the lower alcohol. The preferable alcohol extracting process is performed by using alcohol with 60-80% by volume of ethanol concentration, under heating. The invention relates to the anti-obesity composition comprising the lipase inhibitor.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention relates to a system for providing senior customized cognitive ability training, comprising: a user terminal; and a service server. The user terminal includes: a content performing device for performing VR training content; a manager terminal used by a manager; and a patient terminal used by a patient with mild cognitive impairment. The service server communicates with the user terminal, and provides a training content and dementia prevention managing system. The service server includes: a database unit; a user managing unit; and a training content unit. The database unit stores various pieces of information and data. The user managing unit includes: a cognitive state diagnosing module which allows health information of a user and cognitive state information of the user to be inputted, and firstly diagnoses and evaluates a cognitive state of the user based on inputted user information; an evaluating module which classifies the cognitive state of the user for each function based on the cognitive state of the user evaluated by the cognitive state diagnosing module, and provides each rating to each cognitive state; and a content providing module which provides proper training content to the user based on cognitive state rating information of the user determined in the evaluating module. The training content unit includes: a content selecting module which allows the user to input a play type for performing training content suitable for preferences; and a content executing module which executes the training content depending on needs of the user by considering all options selected by the user in the content selecting module among a plurality of training contents provided in the content providing module of the user managing unit. The present invention efficiently trains cognitive ability of seniors.
OBJECTIVE: Several factors are involved in the preservation of graft function after surgical myocardial revascularization. This follow-up study aimed to evaluate the effects of vein graft anastomosis and graft morphology on long-term graft patency a minimum of 10 years after aortocoronary bypass grafting.Setting and Cohorts. This was a sub-analysis of a study that enrolled patients after isolated bypass surgery at the University Hospital Ostrava in order to evaluate the long-term graft patency of the saphenous vein after endoscopic harvest, a minimum of 10 years after aortocoronary bypass grafting.
METHODS: Fifty angiograms, with a total of 90 grafts, after isolated myocardial revascularization were visualized using coronary computed tomography angiography, with 50% luminal stenosis or greater considered significant.
RESULTS: The overall graft patency rate was 72.3%. The differences in occlusion rates between sequential and individual grafts were not statistically significant (P=0.156). All y-grafts were totally occluded. Graft and target artery diameters had a statistically significant influence on patency (P=1.000 and 0.381, respectively). Longer graft length and higher calcium scores were associated with statistically significant graft occlusion (P=0.033 and 0.005, respectively).
CONCLUSION: Sequential grafts can be constructed safely, especially when the goal is complete myocardial revascularization.
Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
In accordance with the present invention, a cDNA clone encoding a new human  beta  subunit which was designated  beta 5 was found. Probes for this nucleotide sequence are described. In addition, the  beta 5 protein, its associated subunit and its cell distribution were characterized. In another embodiment, this invention relates to assays for detecting this protein.  beta 5 subunit was found present on carcinomas, but absent from lymphoid cells. Consequently, this protein can be used to determine the presence of carcinoma.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is commonly used in clinical practice to detect tumor blood supply, and it has recently been applied to assess skeletal vasculature. In this study, we retrospectively analyzed DCE-MRI data from 37 patients with osteonecrosis of the femoral head to evaluate alterations in microvascular circulation of the femoral head. Time-intensity curves (TICs) in the region of interest were classified into different lesion stages. In the greater trochanter area, extracellular space volume per unit volume of tissue was significantly higher in Association Research Circulation Osseous (ARCO) stage III than in ARCO stage II (P<.05 and power ≥ 0.8), while other parameters showed no statistical difference (P>.05 and/or power < 0.8). In the necrotic area, contrast enhancement ratio and maximum slope of increase were significantly lower in ARCO stage III than in ARCO stage II (P<.05 and power ≥ 0.8), while other parameters showed no statistical difference (P>.05 and/or power < 0.8). In the repair reaction area, all parameters were significantly higher in ARCO stage III than in ARCO stage II (P<.05 and power ≥ 0.8). TIC classification showed that the greater trochanter area mainly exhibited type C (plateau type), the necrotic area mainly exhibited type B (out-flow type), and the repair reaction area mainly exhibited type A (inflow type). We believe that the exchange capacity of the vessels has a much greater impact on femoral head necrosis than the number of vessels, while the generation of the repair area greatly affects the prognosis of femoral head necrosis. These findings suggest that DCE-MRI can provide a good assessment of osteonecrosis of the femoral head perfusion and can serve as a new reference for clinical treatment decisions. [Orthopedics. 2024;47(2):e73-e78.].
Participants enrolled at US sites will receive cusatuzumab 10 mg/kg and potentially escalate to 20 mg/kg IV in combination with azacitidine 75 mg/m\^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies). Participants enrolled from ex-US sites will receive cusatuzumab 20 mg/kg and potentially de-escalate to 10 mg/kg IV in combination with azacitidine 75 mg/m\^2 SC or IV plus venetoclax ramp-up to 400 mg orally (as background therapies).
PURPOSE:To obtain a hypotensive agent, containing superoxide dismutase (HB-SOD) having a heparin-binding site added thereto as an active ingredient without any side effects. CONSTITUTION:A hypotensive agent containing HB-SOD in which a heparin- binding side, e.g. a peptide represented by an amino acid sequence expressed by formula I to III is added to superoxide dismutase (SOD) without essentially having the heparin-binding part as an active ingredient. The HB-SOD is extremely stable in blood, has directing properties for tissues including the liver and is capable of binding to the surfaces of various tissual cells and their vascular inner walls and eliminating the superoxide in the affected part. Oligonucleotides, corresponding to the heparin-binding peptide and synthesized by dividing into several fragments are phosphorylated, annealed and then bound to carboxyl terminals of human erythrocytic type SODcDNA to construct HB-SOD gone, which is then integrated into an expression vector. An yeast is subsequently transformed and the resultant transformant is then cultured to afford the objective HB-SOD.